All News

Methotrexate: shall we split up? Methotrexate (MTX) is widely used in rheumatic diseases yet poses common tolerance issues, especially for the oral form; and bioavailability is known to be limited for doses over 15mg. https://t.co/txCIkgtvzP https://t.co/Mk8FLy4jO3

Methotrexate: shall we split up? | RheumNow

How do we manage difficult discussions about pregnancy in RA? Most rheums know that it is important to get pregnancy planning right for women of childbearing age living with rheumatic diseases. That is easier said than done, though... https://t.co/cXtqqVv6fp https://t.co/k5afTUKYf8

How do we manage difficult discussions about pregnancy in RA? | RheumNow

L20 at #ACR23 Phase 3 RCT of #Telitacicept vs. placebo in #RA ☝🏻B-cell neutralization by targeting BlyS and APRIL ✅ better ACR20 and 50 response at W24 ✅ favorable structural response ✅ good safety profile ❓ few seronegative patients A new small molecule to treat #RA? PAJ https://t.co/fyrqAya41e

#ACR23 #EdLovering presenting on association b/w #RA, #CVD & #Dementia: 👉🏻CVD is not a signif mediator b/w RA &Dementia 👉🏻 signif synergy b/w RA & CVD on dementia (HR 2.45 vs those w/o RA&CVD) 👉🏻 ⬆️ risk of dementia in RA mostly in people with RA+CVD #Mayoclinicrheumatology https://t.co/5kqs3HAACn

The dynamic Dr. Vinod Chandran, talking about metabolomics in #psoriaticDisease #ACR23 The metabolomics facility was established recently at the @UHN @UofT @SchroederInst and we are already seeing the results. @KrembilF @CRASCRRheum @UofTRheum https://t.co/Azxq3k8w5g

Impressive and important study supporting safety of TNF inhibitors among patients with RA-ILD. Elegant methods of target trial emulation. Congrats to the authors on plenary presentation! #ACR23 https://t.co/P7keAoOX7M

🔥 HOT OFF THE PRESS for #ACR23 Effectiveness of a fourth dose of #COVID19 mRNA #vaccine in patients with systemic autoimmune rheumatic diseases using DMARDs: an emulated target trial https://t.co/bvc75BP4aG @zach_wallace_md @jeffsparks https://t.co/CAlgjvUr9X

Something to listen to on the way home from #ACR23 The last episode in a 4 part series on the environment and autoimmunity What does silica exposure have to do with autoimmunity? https://t.co/2Vqi22xqCw

Nipocalimab (say it a couple of times) is a FcRn (neonatal Fc receptor) inhibitor. In short promotes degradation of IgG incl autoantibodies (and investigated in myasthenia). Prof Taylor presents that it might work in CCP high titer RA at #ACR23. #ACRambassador @ACRheum https://t.co/DqlsOv7AVI

Reminder of data for dose reduction #bDMARD by Prof Emery #ACR23 Feasible after early remission induction https://t.co/WwiNp8WKDC

Thanks #ACR23 for a wonderful meeting ! Presented a really positive phase 2 clinical trial results of Dazukibart, an IFN beta monoclonal antibody in #Myositis (DM) #pfizer .Strong efficacy with rapid onset. Safe & tolerable monthly IV injection. Looking forward to start Phase 3. https://t.co/580ICHM8Hs

Just presented at #ACR23 by Dr Jennifer Hanberg @Jen_LS_Hanberg and published at @TheLancetRheum.! Effectiveness of 4th mRNA COVID dose on breakthrough infection @zach_wallace_md https://t.co/PXc2THn217

Chikungunya - takeaway points 🪔Acute arthritis in large joints , polyarthritis and tenosynovitis in hands 🪔 Associated with travel history to Africa/Asia/Asia Pacific 🪔<5% develop chronic arthritis #ACR23 #ACRambassador https://t.co/yzZDpy70i3

Maintain Vigilance for CV Risk Postpartum in Autoimmune Diseases Pregnant women with ARDs and APS face significantly increased risks of CVEs. This increased risk is often attributed to ARDs, its medications or comorbidities associated with it. https://t.co/KwMEwlr7Af https://t.co/vDt4B8jtt6

Maintain Vigilance for CV Risk Postpartum in Autoimmune Diseases | RheumNow

Look if I’m going to be rheumatology writing on a Wednesday night in LA post-#ACR23 then it might as well be with a bulgogi cheesesteak (loaded with jalapeño) and a negroni @MamaShelterLA https://t.co/OsqKb2EkET

Does anyone feel like Lassie? #Wellness #RheumGR Talk by Dr. Wiles @UTSWIMchief @UTSWRheum https://t.co/7HG4vD95JQ

https://twitter.com/KDAO2011/status/1725172112158048657/photo/1

Congrats Dr Desir @dddesir on becoming @ACRheum President, and the first Black president of the ACR. Read about her work, and her priorities to reduce our workforce shortage & improve the culture of belonging 👇 #ACR23 https://t.co/5Y94Wy1Zl0

I’ll keep on tweeting more @RheumNow, but it’s time for me to leave the #ACR23 conference center. Another year of an incredible scientific program, seeing many friends (although sadly ran out of time to see many too) and a whole lot of rheumatology fun. See you in DC #ACR24! https://t.co/h31abYsipX

#Yr in #Preview #ACR2023 J Buyon Pregnancies in #SLE have high #VTE risk - look at Ob/Gyn guidelines for prophylaxis of LMW #heparin - all SLE pregnancies recommend #ASA & #HCQ biomarkers for #renal #lupus, #HCQ levels ?aid #Rx -#SLE nephritis low prednisone 2 IS>1 @RheumNow

B cell signalling reduction to treat #RA? Telitacicept RCT showed #efficacy in active RA w MTX -maybe blunted high responses but no active comparator, only #PBO so difficult to compare to current Rx and only from 1 country China. Past bDMARDs not reported L20 @RheumNow @ACRheum

Topics

All News

Do you get our email newsletter?